Journals / Klinik Psikofarmakoloji Bülteni / 2012 / Cilt: 22 - Sayı: 2

Olanzapine bağlı hipernatremi ile giden malign nöroleptik sendrom

Olanzapine-induced neuroleptic malignant syndrome with hypernatremia

Pages
184–186
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein we report the case of a27 year old male patient who developed NMS withhypernatremia and acute renal failure following treatment with olanzapine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic Malignant syndrome (NMS) is a rare butpotentially fatal adverse effect of antipsychotics.
📊
Key Findings & Data:Inaddition, hypernatremia may play a significant rolebefore occurrence of NMS or it may develop secondaryto acute renal failure.
💡
Conclusion & Impact:Herein we report the case of a27 year old male patient who developed NMS withhypernatremia and acute renal failure following treatment with olanzapine.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic Malignant syndrome (NMS) is a rare butpotentially fatal adverse effect of antipsychotics. Inaddition, hypernatremia may play a significant rolebefore occurrence of NMS or it may develop secondaryto acute renal failure. Herein we report the case of a27 year old male patient who developed NMS withhypernatremia and acute renal failure following treatment with olanzapine.

Özet

Malign Nöroleptik Sendrom (MNS) antipsikotiklerinnadir görülen fakat ölümcül olabilen bir yan etkisidir.MNSnin ortaya çıkışında hipernatreminin önemli rolüolabilir ya da akut böbrek yetmezliğine ikincil olarakgelişebilir. Bu yazıda, olanzapin ile tedavi sonrası MNS,hipernatremi ve akut böbrek yetmezliği gelişen 27yaşında bir erkek hasta bildirilmektedir.

🔖

Cite This Article

GÜNAY, H., TÜTÜNCÜ, R., BİLBEY, H. (2022). Olanzapine bağlı hipernatremi ile giden malign nöroleptik sendrom. Klinik Psikofarmakoloji Bülteni, Cilt: 22 - Sayı: 2, 184–186. https://ajindex.com/articles/574433

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG. Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(5): 897-902.
  2. Bajjoka I, Patel T, O’Sullivan T. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med Nov 1997; 30(5): 698-700
  3. Duggal HS, Singh I. Neuroleptic malignant syndrome presenting with acute renal failure. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(4): 1074-5 American Psychiatric Association (APA) (1994) Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV),4th ed, Washington, DC: American Psychiatric Pres. Zantut-Wittmann DE, Garmes HM, Panzan AD, Lima Mde O, Baptista MT. Severe rhabdomyolysis due to adipsic hypernatremia after craniopharyngioma surgery. Arq Bras Endocrinol Metabol 2007; 51(7): 1175-9.
  4. Ahuja N, Palanichamy N, Mackin P, Lloyd A. Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome:report and review of literature. J Psychopharmacol 2010;24(1):125- 30. Denman JP. Hypernatraemia and rhabdomyolysis. Med J Aust 2007; 187 (9): 527-8.
  5. Cao L, Katz RH. Acute Hypernatremia and Neuroleptic Malignant Syndrome in Parkinson Disease. Am J Med Sci 1999; 318(1): 67-8. Védie C, Poinso F,Hemmi F,Rivet B. Major symptomsdifferential diagnosis of neuroleptic malignant syndrome: threereports. Eur Psychiatry 2000; 15(5): 334-7.
  6. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome—a case review. Hum Psychopharmacol 2003; 18(4): 301-9.